Pertuzumab市場規模、佔有率和成長分析：按適應症、療法、劑型、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球Pertuzumab市場價值為 43 億美元，預計到 2025 年將成長至 45.4 億美元，到 2033 年將成長至 69.7 億美元，在預測期（2026-2033 年）內複合年成長率為 5.5%。

Pertuzumab是一種抑制HER2二聚化的單株抗體，也是HER2陽性癌症治療市場蓬勃發展的核心。帕妥珠單抗曾是一種小眾治療選擇，但其在轉移性乳癌中的療效使其成為一線標準療法，並創造了可觀的收入。 HER2擴增腫瘤廣泛存在於包括乳癌和胃癌在內的多種癌症中，這進一步凸顯了市場的重要性。多項重要的臨床試驗表明，帕妥珠單抗顯著改善了治療效果，促使其在醫療系統中廣泛應用。帕妥珠單抗適應症的拓展（超出乳癌範圍）進一步豐富了市場需求，推動了製藥公司加強投資並努力簡化報銷流程。生物相似藥的興起，得益於人工智慧在研發和市場分析方面的進步，正在改善藥物的可及性，尤其是在低收入地區，從而加速收入成長，並鞏固Pertuzumab在腫瘤治療領域的地位。

全球Pertuzumab市場成長要素

隨著人們對標靶治療的認知不斷提高，醫療專業人員越來越重視精準醫療以改善患者預後，這導致Pertuzumab的需求顯著成長。將Pertuzumab納入現有治療方案，使醫療服務提供者能夠有效滿足患有複雜乳癌亞型患者的需求，進一步增強了人們對該藥物療效的信心。這種整合促使醫院和腫瘤診所將Pertuzumab納入其藥物清單，擴大了其在各種醫療機構中的市場准入，並推動了其持續成長。此外，持續的教育活動和可靠的學術出版物也增強了臨床醫生的信心，並促進了該藥物在多學科醫療團隊中的進一步應用。

全球Pertuzumab市場的限制因素

Pertuzumab的高昂價格給醫療系統帶來了巨大的報銷挑戰，尤其是在財政資源有限的地區。保險公司通常要求提供全面的經濟評估報告，以證明將其納入藥品目錄的合理性，這可能導致患者獲得該藥物的延遲和限制。因此，儘管Pertuzumab的臨床療效已得到證實，醫療機構仍可能選擇更經濟的替代藥物。這種經濟障礙不僅阻礙了市場成長，也加劇了生產者和保險公司之間的談判，最終可能導致保險政策限制該藥物在醫療機構的更廣泛應用。在這種情況下，醫療機構可能被迫考慮為患者提供「同情用藥」方案。

全球Pertuzumab市場趨勢

受腫瘤學領域新型聯合治療的推動，全球Pertuzumab市場正經歷顯著成長。臨床醫生擴大將Pertuzumab納入靶向互補訊號通路的多重藥物聯合療法中，旨在提高HER2陽性惡性腫瘤的治療反應率和存活率。這種向個人化醫療的轉變體現在Pertuzumab與新型抗體、免疫查核點抑制劑和定向小分子藥物的聯合應用上，其目標是克服抗藥性並延長緩解期。隨著這些聯合治療策略的不斷發展，Pertuzumab正逐漸成為現代治療流程中不可或缺的一部分，最終改善患者預後，並鞏固其在全球市場中的重要地位。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球Pertuzumab市場規模：依適應症分類

• HER2陽性乳癌
• 早期乳癌
• 轉移性乳癌
• 術前治療
• 其他

全球Pertuzumab市場規模：依治療類型分類

• 曲妥珠單抗合併化療
• 曲妥珠聯合治療
• 與其他HER2標靶治療合併治療
• 單藥治療（臨床研究）
• 其他

全球Pertuzumab市場規模：以劑型分類

• 靜脈注射
• 用於皮下注射的固定劑量組合藥物
• 其他

全球Pertuzumab市場規模：依最終用戶分類

• 醫院
• 腫瘤中心
• 專科診所
• 學術研究機構
• 其他

全球Pertuzumab市場規模：依通路分類

• 醫院藥房
• 專科藥房
• 直接採購
• 其他

全球Pertuzumab市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• F. Hoffmann-La Roche Ltd.
• Samsung Bioepis Co., Ltd.
• Amgen Inc.
• Celltrion, Inc.
• Sandoz Group AG
• Biocon Biologics Limited
• Dr. Reddy's Laboratories Ltd.
• Shanghai Henlius Biotech, Inc.
• Accord Healthcare Limited
• Pfizer Inc.
• Merck & Co., Inc.
• AstraZeneca plc
• Novartis AG
• Eli Lilly and Company
• Johnson & Johnson
• BeiGene, Ltd.
• Zydus Lifesciences Limited
• Intas Pharmaceuticals Limited
• Alvotech SA
• Teva Pharmaceutical Industries Ltd.

結論與建議

Global Pertuzumab Market size was valued at USD 4.3 Billion in 2024 and is poised to grow from USD 4.54 Billion in 2025 to USD 6.97 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

Pertuzumab, a monoclonal antibody that inhibits HER2 dimerization, is central to the growing market for HER2-positive cancer treatments. This therapeutic option, once niche, has established itself as a frontline standard due to its efficacy in metastatic breast cancer, generating substantial revenues. The relevance of this market is underscored by the prevalence of HER2-amplified tumors in various cancers, including breast and gastric types. Notable clinical trials have highlighted significant improvements in treatment outcomes, driving widespread integration into healthcare systems. Expanding indications beyond breast cancer further diversify demand, prompting pharmaceutical investments and efforts to streamline reimbursement pathways. The rise of biosimilars, supported by AI advancements in development and market analysis, enhances accessibility, particularly in lower-income regions, thereby accelerating revenue growth and solidifying pertuzumab's role in oncology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pertuzumab market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pertuzumab Market Segments Analysis

Global pertuzumab market is segmented by indication, therapy type, dosage form, end user, distribution channel and region. Based on indication, the market is segmented into HER2-Positive Breast Cancer, Early Breast Cancer, Metastatic Breast Cancer, Neoadjuvant Therapy and Others. Based on therapy type, the market is segmented into Combination with Trastuzumab & Chemotherapy, Combination with Trastuzumab, Combination with Other HER2-Targeted Therapies, Monotherapy (Clinical Research) and Others. Based on dosage form, the market is segmented into Intravenous Infusion, Subcutaneous Fixed-Dose Combination and Others. Based on end user, the market is segmented into Hospitals, Oncology Centers, Specialty Clinics, Academic & Research Institutes and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies, Direct Procurement and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pertuzumab Market

The increasing recognition of targeted therapies significantly boosts the demand for pertuzumab, as healthcare professionals increasingly focus on precision treatments that enhance patient outcomes. By incorporating pertuzumab into existing treatment protocols, providers effectively meet the needs of patients with challenging breast cancer subtypes, thereby reinforcing trust in the drug's effectiveness. This integration motivates hospitals and oncology clinics to include pertuzumab in their medication lists, facilitating greater market access and ongoing growth across various healthcare environments. Moreover, continuous educational efforts and reputable publications bolster clinical confidence, encouraging further adoption among interdisciplinary medical teams.

Restraints in the Global Pertuzumab Market

The elevated cost of pertuzumab poses significant reimbursement challenges for healthcare systems, especially in areas with limited financial resources. Payers frequently demand comprehensive economic evaluations to justify formulary inclusion, which can lead to delays or restrictions in patient access to the medication. As a result, healthcare providers may choose more affordable alternatives, despite pertuzumab's proven clinical effectiveness. This financial obstacle not only stifles market growth but also heightens negotiations between manufacturers and insurers, potentially leading to restrictive coverage policies that limit wider acceptance in treatment facilities. This scenario may force institutions to explore compassionate use options for their patients.

Market Trends of the Global Pertuzumab Market

The global pertuzumab market is experiencing significant growth driven by the rising trend of emerging combination therapies in oncology. Clinicians are increasingly incorporating pertuzumab into multi-agent treatment regimens that target complementary pathways, thereby aiming to enhance therapeutic responses and improve survival rates in patients with HER2-positive malignancies. This shift toward personalized medicine is reflected in the strategic use of novel antibodies, immune checkpoint inhibitors, and targeted small molecules alongside pertuzumab, which aims to overcome treatment resistance and increase remission durability. As these combination strategies evolve, pertuzumab is positioned as a vital component within modern treatment algorithms, ultimately improving patient outcomes and solidifying its relevance across global markets.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Pertuzumab Market Size by Indication & CAGR (2026-2033)

• Market Overview
• HER2-Positive Breast Cancer
• Early Breast Cancer
• Metastatic Breast Cancer
• Neoadjuvant Therapy
• Others

Global Pertuzumab Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Combination with Trastuzumab & Chemotherapy
• Combination with Trastuzumab
• Combination with Other HER2-Targeted Therapies
• Monotherapy (Clinical Research)
• Others

Global Pertuzumab Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Intravenous Infusion
• Subcutaneous Fixed-Dose Combination
• Others

Global Pertuzumab Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Oncology Centers
• Specialty Clinics
• Academic & Research Institutes
• Others

Global Pertuzumab Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Direct Procurement
• Others

Global Pertuzumab Market Size & CAGR (2026-2033)

• North America (Indication, Therapy Type, Dosage Form, End User, Distribution Channel)
  • US
  • Canada
• Europe (Indication, Therapy Type, Dosage Form, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Therapy Type, Dosage Form, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Therapy Type, Dosage Form, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Therapy Type, Dosage Form, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Biologics Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Henlius Biotech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accord Healthcare Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alvotech S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations